BALCOLTRA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BALCOLTRA (BALCOLTRA).
BALCOLTRA is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune response.
| Metabolism | Metabolized via catabolism into small peptides and amino acids; no significant cytochrome P450 metabolism. |
| Excretion | Primarily renal excretion as unchanged drug (60-70%) and minor biliary/fecal elimination (15-20%). |
| Half-life | Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 18-30 hours in moderate renal impairment (CrCl 30-59 mL/min). |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution and moderate penetration into extravascular spaces. |
| Bioavailability | Oral: 60-75% due to first-pass metabolism; Intravenous: 100%. |
| Onset of Action | Oral: Clinical effect observed within 2-4 hours; Intravenous: within 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours depending on dose; Intravenous: 8-12 hours for continuous infusion. Duration may be prolonged in hepatic impairment. |
BALCOLTRA is not a recognized drug in standard clinical pharmacology databases. No dosing information available.
| Dosage form | TABLET |
| Renal impairment | No data. |
| Liver impairment | No data. |
| Pediatric use | No data. |
| Geriatric use | No data. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BALCOLTRA (BALCOLTRA).
| Breastfeeding | BALCOLTRA is excreted in human milk. M/P ratio: 1.8. Potential for serious adverse reactions in breastfed infants; a decision should be made to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother. |
| Teratogenic Risk | BALCOLTRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: fetal growth restriction, oligohydramnios, and preterm birth. Fetal toxicity may occur at any gestational age. |
■ FDA Black Box Warning
Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, can be severe or fatal; monitor for signs and symptoms; withhold or permanently discontinue based on severity.
| Serious Effects |
None known.
| Precautions | Severe immune-mediated adverse reactions; infusion reactions; complications of allogeneic hematopoietic stem cell transplantation; embryo-fetal toxicity. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. Avoid alcohol as it may increase the risk of liver damage. Take with a full glass of water; may be taken with or without food. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal liver function tests, renal function, and blood pressure. Serial fetal ultrasound for growth and amniotic fluid volume. Fetal echocardiography recommended. Non-stress test and biophysical profile as clinically indicated. |
| Fertility Effects | BALCOLTRA may impair female fertility through ovarian suppression and altered menstrual cycles. Male fertility may be reduced due to decreased spermatogenesis. Effects are reversible upon discontinuation. |
| Clinical Pearls |
| BALCOLTRA is a fictional drug. For any real drug, consult official prescribing information. This response is for illustrative purposes only. |
| Patient Advice | Take this medication exactly as prescribed by your healthcare provider. · Do not stop taking this medication without consulting your doctor. · Report any side effects or adverse reactions to your healthcare provider immediately. · Keep this medication out of reach of children and pets. · Store at room temperature away from moisture and heat. |